{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:12:18Z","timestamp":1779225138716,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.idcr.2022.e01460","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T23:02:28Z","timestamp":1645743748000},"page":"e01460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone"],"prefix":"10.1016","volume":"27","author":[{"given":"Luis A.","family":"Marcos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Kirkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2022.e01460_bib1","unstructured":"Tafenoquine (Arakoda; Krintafel) for malaria, Med Lett, 61, 2019, pp. 101\u2013104."},{"key":"10.1016\/j.idcr.2022.e01460_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QCO.0000000000000574","article-title":"Tafenoquine: the new kid on the block","volume":"32","author":"Chen","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.4269\/ajtmh.19-0001","article-title":"Approval of Tafenoquine for malaria chemoprophylaxis","volume":"100","author":"Berman","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.idcr.2022.e01460_bib4","first-page":"659","article-title":"Pharmaceutical approval update","volume":"43","author":"Kaufman","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.idcr.2022.e01460_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4269\/ajtmh.1998.58.645","article-title":"First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial","volume":"58","author":"Brueckner","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.idcr.2022.e01460_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/AAC.41.1.91","article-title":"Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model","volume":"41","author":"Marley","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idcr.2022.e01460_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/infdis\/jiz119","article-title":"Could the drug Tafenoquine revolutionize treatment of Babesia microti infection?","volume":"220","author":"Mordue","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13071-020-04235-7","article-title":"Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo","volume":"13","author":"Carvalho","year":"2020","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.idcr.2022.e01460_bib9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/cid\/ciaa131","article-title":"Serious infectious complications after rituximab therapy in patients with autoimmunity: Is this the final word?","volume":"72","author":"Gkrania-Klotsas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2016.02.016","article-title":"Persistence of babesiosis for>2 years in a patient on rituximab for rheumatoid arthritis","volume":"85","author":"Raffalli","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/cid\/ciab050","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis","volume":"72","author":"Krause","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idcr.2022.e01460_bib14","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia","volume":"65","author":"Simon","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idcr.2022.e01460_bib15","doi-asserted-by":"crossref","first-page":"16079","DOI":"10.1038\/nmicrobiol.2016.79","article-title":"A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse","volume":"1","author":"Lemieux","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.idcr.2022.e01460_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMe1816383","article-title":"Tafenoquine--- a radical improvement?","volume":"380","author":"White","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2022.e01460_bib17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jcph.302","article-title":"Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects","volume":"54","author":"Green","year":"2014","journal-title":"J Clin Pharmacol"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250922000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250922000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:05:42Z","timestamp":1761998742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250922000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":17,"alternative-id":["S2214250922000889"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2022.e01460","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2022.e01460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01460"}}